Research
Hormonal
Semaglutide reduces cardiovascular risk (MACE) and non-ASCVD deaths (including from infections) in overweight/obese patients with established cardiovascular disease, independent of diabetes status.
If you are overweight or obese and have heart disease, semaglutide 2.4mg weekly can reduce your risk of heart attack, stroke, and death by 20%, even if you don't have diabetes. It may also reduce death from infections.
StrongSupportsHIGH confidence
Semaglutide also showed a 20% reduction in MACE in overweight or obese adults with preexisting ASCVD but without diabetes, according to the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial... patients treated with semaglutide 2.4 mg presented a significant reduction in non-ASCVD deaths, especially deaths from infections.
Why this rating
Based on the SELECT trial, a major clinical trial with robust human data.
Source
Spotlight on the Mechanism of Action of Semaglutide
Ilias Papakonstantinou et al. · Current Issues in Molecular Biology · 2024
DOI 10.3390/cimb46120872
narrative_reviewCited 42×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide improves insulin sensitivity and glucose uptake in skeletal muscle and adipose tissue by activating the PI3K/AKT and AMPK/SIRT1 pathways, leading to GLUT4 translocation, independent of direct insulin action in some contexts.Moderate
- Semaglutide (2.4 mg once weekly) promotes adipose tissue browning and mitochondrial biogenesis via the AMPK/SIRT1/PGC1α/UCP1 axis, enhancing energy expenditure and thermogenesis, although this mechanism is primarily established in preclinical rodent models rather than confirmed in humans.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →